SCHEMBL684835

SCHEMBL684835

Cc1cccc(C(=O)N/N=C/c2ccccc2O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.72
PIK3CG P48736 1/20 0.68
KMT2A Q03164 7/20 0.67
HTT P42858 3/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
POLB P06746 3/20 0.67
TDP1 Q9NUW8 3/20 0.67
LMNA P02545 2/20 0.67
KDM4E B2RXH2 2/20 0.67
PTBP1 P26599 1/20 0.67
DUSP3 P51452 1/20 0.66
PTPN5 P54829 1/20 0.66
PTPN11 Q06124 1/20 0.66
MAOA P21397 1/20 0.64
MAOB P27338 1/20 0.64
NPC1 O15118 5/20 0.62
RAB9A P51151 4/20 0.62
L3MBTL1 Q9Y468 1/20 0.61
MEN1 O00255 4/20 0.61
MAPT P10636 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22367607 0.91 KMT2A (0.62) KDM1APIK3CGKMT2AHTTSMN1; SMN2
SCHEMBL21145694 0.91 KMT2A (0.62) KDM1APIK3CGKMT2AHTTSMN1; SMN2
SCHEMBL21145692 0.91 KMT2A (0.62) KDM1APIK3CGKMT2AHTTSMN1; SMN2
SCHEMBL15127234 0.89 PIK3CG (0.61) KDM1APIK3CGKMT2AHTTSMN1; SMN2
SCHEMBL685021 0.89 KDM1A (0.61) KDM1APIK3CGKMT2AHTTSMN1; SMN2
SCHEMBL683817 0.89 KDM1A (0.68) KDM1APIK3CGKMT2AHTTSMN1; SMN2
SCHEMBL27178065 0.88 RAB9A (0.63) KDM1AKMT2AHTTSMN1; SMN2POLB
SCHEMBL27178059 0.88 RAB9A (0.63) KDM1AKMT2AHTTSMN1; SMN2POLB
SCHEMBL30826069 0.88 RAB9A (0.63) KDM1AKMT2AHTTSMN1; SMN2POLB
SCHEMBL20175461 0.87 SIRT1 (0.64) KDM1AKMT2AHTTSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238140-A1 Compounds for Targeting Cancer Stem Cells THE GENERAL HOSPITAL CORPORATION 2021-08-05 US disclosed
US-8791298-B2 Use of metal hydrazide complex compounds as oxidation catalysts BASF SE (DE) 2014-07-29 US disclosed
US-8791298-B2 Use of metal hydrazide complex compounds as oxidation catalysts BASF SE (DE) 2014-07-29 US disclosed
US-8680150-B2 Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors LIGAND PHARMACEUTICALS, INC. (US) 2014-03-25 US disclosed
US-8680150-B2 Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors LIGAND PHARMACEUTICALS, INC. (US) 2014-03-25 US disclosed
US-20130281353-A1 Use of Metal Hydrazide Complex Compounds as Oxidation Catalysts BASF SE (DE) 2013-10-24 US disclosed
US-20130281353-A1 Use of Metal Hydrazide Complex Compounds as Oxidation Catalysts BASF SE (DE) 2013-10-24 US disclosed
US-8492324-B2 Use of metal hydrazide complex compounds as oxidation catalysts BASF SE (DE) 2013-07-23 US disclosed
US-8492324-B2 Use of metal hydrazide complex compounds as oxidation catalysts BASF SE (DE) 2013-07-23 US disclosed
US-20120010075-A1 SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER DOW AGROSCIENCES LLC (US) 2012-01-12 US disclosed
US-20120010075-A1 SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER DOW AGROSCIENCES LLC (US) 2012-01-12 US disclosed
US-20110071066-A1 USE OF METAL HYDRAZIDE COMPLEX COMPOUNDS AS OXIDATION CATALYSTS BASF SE (DE) 2011-03-24 US disclosed
US-20110003851-A1 SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS LIGAND PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003851-A1 SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS LIGAND PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071066-A1 USE OF METAL HYDRAZIDE COMPLEX COMPOUNDS AS OXIDATION CATALYSTS SOD1, H1-4, H1-5 KDM1A 505/4885PIK3CG 3391/4885KMT2A 453/4885
US-20120010075-A1 SYNERGISTIC FUNGICIDAL COMPOSITIONS INCLUDING HYDRAZONE DERIVATIVES AND COPPER SOD1, CYP51A1, SOD3 KDM1A 484/4885PIK3CG 2876/4885KMT2A 1362/4885
US-20110003851-A1 SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS MPL, CSF3R, CSF1R KDM1A 2673/4885PIK3CG 1929/4885KMT2A 887/4885
US-20210238140-A1 Compounds for Targeting Cancer Stem Cells G3BP1, G3BP2, HMGB2 KDM1A 2810/4885PIK3CG 2805/4885KMT2A 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.